Regency Centers Reports First Quarter 2024 Results JACKSONVILLE, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency Centers”, “Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the period ended March 31, 2024 and provided updated 2024 earnings guidance. For the three months ended March 31, 2024 and 2023, Net Income Attributable to Common Shareholders was $0.58 per diluted share and $0.57 per diluted share, respectively. First Quarter Highlights Reported Nareit FFO of $1.08 per diluted share and Core Operating Earnings o...
Tyson Foods To Participate in 19th Annual BMO Global Farm to Market Conference SPRINGDALE, Ark., May 02, 2024 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) announced today that management will participate in the 19th Annual BMO Global Farm to Market Conference on May 15, 2024 in New York City. The fireside chat with Donnie King, president & CEO, and John R. Tyson, executive vice president & CFO, will begin at approximately 8:00 a.m. Eastern Time and will be available via a live webcast. The webcast link, replay, and other information can be accessed on the company’s investor relations...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the millions of people living with hepatitis delta,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer. “Our team has worked diligently to streamline our operations and reduce costs,...
Pilgrim’s Pride Reports First Quarter 2024 Results with $4.4 Billion in Net Sales and Operating Income of $250.3 Million GREELEY, Colo., May 01, 2024 (GLOBE NEWSWIRE) -- Pilgrim’s Pride Corporation (NASDAQ: PPC), one of the world's largest poultry producers, reports its first quarter 2024 financial results. First Quarter Highlights Net Sales of $4.4 billion.Consolidated GAAP operating income margin of 5.7%.GAAP Net Income of $174.9 million and GAAP EPS of $0.73. Adjusted Net Income of $182.9 million or Adjusted EPS of $0.77.Adjusted EBITDA of $371.9 million, or a 8.5% margin, with adjus...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards ...
Occidental Announces Dividend HOUSTON, May 01, 2024 (GLOBE NEWSWIRE) -- (NYSE: OXY) announced today that its Board of Directors declared a regular quarterly dividend of $0.22 per share on common stock, payable on July 15, 2024, to stockholders of record as of the close of business on June 10, 2024. About Occidental is an international energy company with assets primarily in the United States, the Middle East and North Africa. We are one of the largest oil and gas producers in the U.S., including a leading producer in the Permian and DJ basins, and offshore Gulf of Mexico. Our midstre...
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years (2020-2022)1Although symptoms are present in childhood, a significant portion of women with ADHD don’t receive a diagnosis until they are adults2 ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals ...
Norwegian Cruise Line Holdings Reports Strong First Quarter 2024 Financial Results Revenue up 20% year-over-year on strong demand Company beat Q1 guidance across key metrics and raises full year guidance based on strong revenue MIAMI, May 01, 2024 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the first quarter ended March 31, 2024 and provided guidance for the second quarter and full year 2024. First Quarter 2...
Two Directors at Helmerich & Payne Inc sold 25,910 shares at between 40.220USD and 40.490USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is an immunology company focused on powering the immune syst...
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United Sta...
Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.
UMB Announces Agreement to Acquire Heartland Financial Largest acquisition in UMB history will increase total assets by more than 40% and significantly expand geographic footprint UMB investment community call today, Monday, April 29, at 7:30 a.m. (CT) / 8:30 a.m. (ET) KANSAS CITY, Mo. and DENVER, April 29, 2024 (GLOBE NEWSWIRE) -- UMB Financial Corporation (Nasdaq: UMBF) and Heartland Financial, USA Inc. (Nasdaq: HTLF) announced today that they have entered into a definitive merger agreement under which UMB Financial Corporation (UMB) will acquire Heartland Financial USA, Inc. (HTLF),...
Heartland Financial USA, Inc. ("HTLF") Reports Quarterly Results as of March 31, 2024 First Quarter Highlights •Quarterly net income available to common stockholders of $49.7 million or $1.16 per common share•Adjusted earnings available to common stockholders of $52.4 million or $1.22 adjusted diluted earnings per common share, which excludes $1.4 million of acquisition, integration and restructuring costs and $2.0 million of FDIC special assessment expense•Common equity ratio increased to 9.76%; Tangible common equity ratio (non-GAAP) improved 35 basis points to 6.88%•Net interest margin,...
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with approval Conference call and webcast to be hosted today at 8:30 am ET BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the im...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.